Researchers at Stanford University have developed a novel platform for genetically engineering cells within a living organism, circumventing previous limitations related to accessing target tissues and the size of the genetic payload.
Stanford researchers have developed a high-sensitivity cell-based assay for predicting the innate immune response to recombinant adeno-associated virus.